Mother-of-three Nancy Roos has a relentless, fighting spirit. She found she had breast cancer twelve weeks into her pregnancy with her now 10-month-old girl Isabella, but declined to end. And now she’s in a battle with her medical help, Fedhealth, which is refusing to pay for full treatment with the revolutionary breast cancer drug Herceptin. Roos was diagnosed last year with HER2-positive ( Human Epidermal Expansion Factor Receptor two ), an assertive type of cancer with a poor diagnosis if it is treated with typical chemo only. It has also got a really high recurrence rate. Nevertheless Herceptin, given over twelve months, has been proved to noticeably cut back the prospect of the cancer returning after it’s been treated with chemo, surgery and radiation treatment. Her doctor, Devan Moodly, has written one or two letters of inducement, pointing to the “ample proof that one year of Herceptin treatment offers sustained disease-free survival keeping patients longer without illness recurrence”.
In 2006 Discovery Health made the front page when 4 girls with breast cancer took them on, and won the prerogative to be handled with Herceptin. Roos asserted her medical help costs her R10 000 a month for her folks of 5 Fedhealth’s top charge. Yet she found out that ladies that aren’t on medical help were accessing Herceptin free at some state infirmaries. Roos’s world modified in May last year when, agitated by a swollen stomach, she visited her gynaecologist. Thinking it was somehow related to breastfeeding her child Mila, now 2, she was startled to learn she was twelve weeks pregnant. But her joy was eclipsed by the gynaecologist finding a pile in her left breast. She was sent to a radiologist for further tests.
She knew something was wrong when she was called to the gynaecologist’s rooms a couple of days later on. And then he suggested her to end the pregnancy, which may be compromised by the chemo she wanted to fight the cancer. There were nonetheless, more shocks to come ; a lady oncologist from Pretoria, an expert in breast cancer, warned her that if she didn’t cancel straight away, she would die. But Roos sought a second opinion, and Moodly, from Milpark Surgery , created therapy plan.
He advised “safe” chemo that wouldn’t be dangerous to the baby, and early delivery at seven-and-a-half months by Caesarean section.
Afterward , she would receive full-strength chemo, with Herceptin, to shrink the swelling. She would then go through surgery to get rid of the shrivelled up growth and lymph nodes, followed by radiation care. Eventually , she would take Herceptin for a year to stop the cancer reoccurring. It was actually the final point of the plan which proved tricky.
Regardless of having upgraded to Fedhealth’s premier membership, Maxima And , because on paper it guaranteed unlimited oncology benefits, Roos was in for a surprise. After Isabella was born last Nov , and requests for payment for Herceptin went to the medical help, Fedhealth replied it was a biologic, and they would pay just for 3 injections over 9 weeks. Roos threatened court action, which got the notice of Fedhealth’s principal officer, Katy Caldis, who wrote in Jan that because of the special circumstances of Roos being diagnosed when carrying the baby, they’d give her an extra R97 000 to help in funding the Herceptin. Roos and her partner, tired from their battle with Fedhealth, made a decision to sell their farm to back the rest of the treatment. But getting Fedhealth to switch its policy on Herceptin remains Roos’s mission. Peter Jordaan, Fedhealth’s selling executive, recounted Herceptin cases were always terribly troublesome. “We have funding rules and customs that take account of the systematic proof for any particular treatment’s efficacy and safety in addition to its cost-effectiveness and cost. The jury is still out on how Herceptin is administered most optimally, i.e. Available systematic proof can’t let us know which course of treatment is best.” He requested a trial comparing the efficacy and safety of diverse approaches, announcing that just when such results became available would any claims concerning the supremacy of one period of treatment vs another be made.
But Jordaan charged the manufacturer constantly subsidized only research associated with the 1 year program.
